Aktienanalyse zu ADMA Biologics, Inc. (ADMA)ADMAADMA Biologics, Inc.

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ADMA Biologics is a good buy right now, primarily due to its recent strong earnings report showing a 2% year-over-year revenue increase to $124.4 million and a gross margin of 69% in Q2 2026. Despite a year-to-date decline of 42.06%, the stock has shown a positive trend with a 5-day change of +6.58% and strong insider buying activity increasing by 719.51% over the last quarter, indicating confidence in the company's future performance.

4 analysts cover ADMA: 4 rate it Buy, 0 Hold and 0 Sell.